"Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The data collected is typically used to explain, influence and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data." Digital biomarkers journal
Now in its fourth year hosted in partnership with Roche in Basel, the Digital Biomarkers in Clinical Trials Summit is the first and only global forum of its kind to focus on ways for pharma clinical trials to take advantage of new opportunities to collect better data and improve the patient experience; as well as how these new digital health tools supplement existing biomarker strategies.

Join 15+ speakers, 250+ senior-level pharma, clinical trials, technology and digital health executives virtually on June 23rd, 2021 at Roche in Basel to learn, network, develop and improve the way pharma clinical trials utilize mobile-enabled, wearables, and IoT capabilities to improve existing biomarker strategies, improve patient experience and collect better data.

Global experts converge at the forefront of wearable sensor technology, data management, analytics, connected device & biomarkers strategies in clinical trials. If you’re involved with R&D, sales & marketing, information technology, data management, patient recruitment, retention, adherence, digital health, digital biomarkers, quantitative or translational medicine - this is the place to be.
Location
VIRTUAL MEETING
Date & Time
23 June 2021, 13:00 - 17:00 Basel Time (GMT+2)
IN PARTNERSHIP WITH:
2021 DIGITAL BIOMARKERS SUMMIT AGENDA TOPICS

OVERALL THEMES:

1. The State of Digital Biomarkers Today

Where does the industry stand currently?

2. Digital Biomarker Development Amidst the COVID-19 Pandemic


Challenges for ongoing Clinical Trials
Comparison between Site-based and De-Centralized Trials
Which features seem to be stable during the Pandemic?
Adherence Challenges & Successes in times of Quarantine
Impact of Regulatory Responses on the Clinical Trials
Missing clinical validation data - was the pandemic too early?


3. Digital Biomarkers Post-COVID

What will be different after the Pandemic?
What is holding us back from our Endpoints?
Has the Pandemic slowed down the use of Digital Biomarkers, or not?
What have we learned so far?
Cross Industry Collaboration - can Digital Biomarkers be like Vaccines?


2021 Conference Agenda
13:00 AM

Welcoming Words & Introduction

Chairperson: Christian Gossens, Global Head, Digital Biomarkers, Roche
13:10 PM

Opening Remarks from Roche


13:15 PM

KEYNOTE PANEL: The State of Digital Biomarkers Today



• State of the art pipelines to transfer data from patient to data scientist
• Applications of AI and Machine Learning
• A discussion of analytic automation and visualization best practices
• Transforming clinically relevant symptoms into digitally measurable biomarkers

Led by:
Christian Gossens, Global Head, Digital Biomarkers, Roche

Jen Goldsack, Executive Director, Digital Medicine Society (DiMe)
Ruth Schneider, Assistant Professor of Neurology, Center for Health + Technology, University of Rochester 
13:30

MICRO BREAK
13:35

HIGHLIGHTS OF THE YEAR IN DIGITAL BIOMARKERS
13:35

CHeT CASE STUDY: The Future of Clinical Trials - Decentralized Studies & Digital Biomarkers

Ruth Schneider, Assistant Professor of Neurology, Center for Health + Technology, University of Rochester 

13:55

CASE STUDY: The Pursuit of Novel Digital Endpoints

Speaker TBA
14:15

BREAK


Sponsor: PhysIQ
14:25-15:05

CASE STUDIES TBA


15:05

PHYSIQ Panel Discussion: Taking off the training wheels with Digital Biomarkers in Clinical Trials

In this “conceptual” case study that combines lessons from actual cases (while protecting identities), we consider use of sensors to support digital endpoints in a hypothetical HF study. We suggest it is time to take off the training wheels with respect to adoption of scalable biosensor data in clinical trials. We contrast alternate approaches to designing in wearable sensors and the risks of ad hoc sensor choice. We examine messaging that can be used by digital health thought leaders to educate their audiences about pertinent choices for selecting infrastructure for driving optimal use of digital biomarkers.


Matt Pipke, CTO, PhysIQ
Chris Economos, COO, PhysIQ
Speaker TBA, Janssen
Speaker TBA, Lilly

15:25

BREAK


Sponsor: PhysIQ
15:40

OUTLOOK FOR DIGITAL BIOMARKERS
 

15:40

CASE STUDY: Adherence and Missing Clinical Validation Data in Time of the Pandemic

Florian Lipsmeier, Data Analysis Team Lead for Digital Biomarkers, Roche

16:00

CASE STUDY TBA


16:20

MICRO BREAK
16:25

PANEL DISCUSSION: Outlook for Digital Biomarkers in the post-COVID-19 Environment

• Next steps for the digital biomarker community
• Discussion of partnerships, regulatory progress
• The pursuit of passive patient monitoring & improved protocol adherence


Arne Müller, Data Scientist, Digital Endpoints, Novartis
Moderator: Christian Gossens, Global Head, Digital Biomarkers, Roche


16:50

Concluding Overall Q&A Session

Led by: Christian Gossens, Global Head, Digital Biomarkers, Roche
Did you miss the Digital Biomarkers Summit 2020?
Sign up below for the complete video coverage and slide decks from each session of the conference.
Digital Biomarkers Summit 2020
Teaser Video
Speakers and Advisors
Christian Gossens
Global Head, Digital Biomarkers
ROCHE
Bryn Roberts
SVP, Global Head of Operations, pRED
ROCHE
Ray Dorsey
Director
UNIVERSITY OF ROCHESTER CENTER FOR HEALTH & TECHNOLOGY
Michelle Crouthamel
Managing Director, Digital Health & Technology
ABBVIE
Sohini Chowdhury
Deputy CEO
MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH
Shibeshih Belachew
Sr. Medical Dir., Head of ECD for MS
biogen
Kirsten Taylor
Biomarker and Experimental Medicine Leader
ROCHE
Arne Müller
Data Scientist, Digital Endpoints
NOVARTIS
Jeremy Wyatt
President
ACTIGRAPH
Nikhil Mahadevan
Data Scientist, Digital & Translational Imaging
PFIZER
Kate Lyden
Lead Scientist
Vivosense
Dudley Tabakin
CEO
Vivosense
Michelle Longmire
CEO
MEDABLE
Hannah Staunton
Principal Clinical Outcomes Scientist
ROCHE
Florian Lipsmeier
Digital Biomarker Data Analysis Team Lead
ROCHE
Matt Pipke
CTO
PHYSIQ
Carrie Northcott
Director, Digital Medicine & Translational Imaging
PFIZER
Yiorgos Christakis
Data Scientist, Digital Medicine & Translational Imaging
PFIZER
Interested in Sponsorship & Exhibition Opportunities?
Conference Highlights from the 2019 Digital Biomarkers Summit hosted at Roche
2020 Conference Presentations
Christian Gossens
ROCHE
Keynote Panel
Roche, Abbvie, Chet, biogen
Ray Dorsey
CHET
Michelle Crouthamel
AbbVie
Kate Lyden & Jeremy Wyatt
Vivosense & ACtigraph
Sohini Chowdhury
MJFF
Nikhil Mahadevan & Yiorgos Christakis
pfizer
Matt Pipke
physiq
Kirsten Taylor, Florian Lipsmeier & Hannah Staunton
roche
Concluding Panel
Mjff, Novartis, roche, Pfizer & vivosense
2019 Conference Presentations
Bryn Roberts
ROCHE
Dan Karlin
HEALTHMODE
Timothy Kilchenmann
ROCHE
Valentin Hamy
GSK
Emilio Merlo Pich
TAKEDA
Ben Vandendriessche
BYTEFLIES
Peter Groenen
IDORSIA
Michelle Longmire
MEDABLE
Ieuan Clay
NOVARTIS
Valeria De Luca
Novartis
Sohini Chowdhury
Michael J FOx Foundation for Parkinson's Research
Arne Müller
NOVARTIS
Historical Conference Photo Gallery
Location
Hosted in Partnership with Roche
The office high-rise, Building 1, is a key pillar of Roche's site development strategy. With its straightforward yet unmistakable design, it blends in perfectly with the Roche grounds and the Basel cityscape. With 41 floors and workspace for around 2,000 employees, the office high-rise also shows a clear commitment to the Basel site.
 Join us at the Digital Biomarkers in Clinical Trials Summit 2021
Where the Industry Meets to Accelerate the Development of Digital Biomarkers

Processing Registration...